Mostra el registre d'ítem simple
Introducing lasso peptides as molecular scaffolds for drug design: Engineering of an integrin antagonist.
dc.contributor.author | Knappe, T.A. |
dc.contributor.author | Manzenrieder, F. |
dc.contributor.author | Mas Moruno, Carlos |
dc.contributor.author | Linne, U. |
dc.contributor.author | Sasse, F. |
dc.contributor.author | Kessler, H. |
dc.contributor.author | Xie, X. |
dc.contributor.author | Marahiel, M.A. |
dc.contributor.other | Universitat Politècnica de Catalunya. Departament de Ciència dels Materials i Enginyeria Metal·lúrgica |
dc.date.accessioned | 2014-04-30T11:26:41Z |
dc.date.created | 2011 |
dc.date.issued | 2011 |
dc.identifier.citation | Knappe, T.A. [et al.]. Introducing lasso peptides as molecular scaffolds for drug design: Engineering of an integrin antagonist.. "Angewandte chemie. International edition", 2011, vol. 50, núm. 37, p. 8714-8717. |
dc.identifier.issn | 1433-7851 |
dc.identifier.uri | http://hdl.handle.net/2117/22784 |
dc.description.abstract | Thumbnail image of graphical abstract Tightening the noose: Lasso peptides are a class of stable bacterial peptides with unique characteristics that encourage their application in drug design. Epitope grafting of the integrin binding motif RGD onto the lasso structure of microcin J25 converts the knotted peptide into a nanomolar integrin antagonist (see picture). Engineered lasso peptides can therefore be used for pharmacophore presentation. |
dc.format.extent | 4 p. |
dc.language.iso | eng |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Spain |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ |
dc.subject | Àrees temàtiques de la UPC::Enginyeria dels materials |
dc.subject.lcsh | Peptides |
dc.subject.lcsh | Drugs--Design |
dc.subject.other | drug design |
dc.subject.other | epitope grafting |
dc.subject.other | integrin inhibitors |
dc.subject.other | lasso peptides |
dc.subject.other | molecular scaffolds |
dc.title | Introducing lasso peptides as molecular scaffolds for drug design: Engineering of an integrin antagonist. |
dc.type | Article |
dc.subject.lemac | Pèptids |
dc.subject.lemac | Medicaments -- Disseny |
dc.identifier.doi | 10.1002/anie.201102190 |
dc.description.peerreviewed | Peer Reviewed |
dc.relation.publisherversion | http://onlinelibrary.wiley.com/doi/10.1002/anie.201102190/abstract |
dc.rights.access | Restricted access - publisher's policy |
local.identifier.drac | 13618817 |
dc.description.version | Postprint (published version) |
dc.date.lift | 10000-01-01 |
local.citation.author | Knappe, T.A.; Manzenrieder, F.; Mas-Moruno, C.; Linne, U.; Sasse, F.; Kessler, H.; Xie, X.; Marahiel, M.A. |
local.citation.publicationName | Angewandte chemie. International edition |
local.citation.volume | 50 |
local.citation.number | 37 |
local.citation.startingPage | 8714 |
local.citation.endingPage | 8717 |
Fitxers d'aquest items
Aquest ítem apareix a les col·leccions següents
-
Articles de revista [960]